Literature DB >> 8659597

Surgical reconstruction of the ocular surface in advanced ocular cicatricial pemphigoid and Stevens-Johnson syndrome.

K Tsubota1, Y Satake, M Ohyama, I Toda, Y Takano, M Ono, N Shinozaki, J Shimazaki.   

Abstract

PURPOSE: Ocular cicatricial pemphigoid and Stevens-Johnson syndrome often cause ocular damage and blindness not amenable to surgical correction. We present a new surgical technique for reconstructing affected eyes.
METHODS: Fourteen eyes of 11 patients with cicatricial keratoconjunctivitis (seven patients with cicatricial pemphigoid and four with Stevens-Johnson syndrome; average age +/- S.D., 55.5 +/- 25.4 years) were treated with a combination of allograft limbal transplantation, amniotic membrane transplantation, and tarsorrhaphy, followed every 15 minutes by artificial tears derived from the patient's blood serum. Eight eyes required concomitant penetrating or lamellar keratoplasty because of corneal opacity.
RESULTS: With a mean follow-up of 143 days (range, 10 to 608 days), we achieved successful ocular surface reconstruction in 12 eyes, with minimal recurrence of symblepharon. Failure occurred in two eyes (one each in 9- and 10-year-old boys) that developed corneal infiltration and vascularization.
CONCLUSIONS: A combination of allograft limbal transplantation, amniotic membrane transplantation, and tarsorrhaphy, followed by the use of serum-derived tears, can reconstruct the ocular surface in most cases. Although in this study the follow-up period was short and relatively few patients were studied, this approach appears to offer an alternative to keratoprosthesis for treating severe cicatricial keratoconjunctivitis with dry eye.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8659597     DOI: 10.1016/s0002-9394(14)71962-2

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  68 in total

1.  Long term results after autologous nasal mucosal transplantation in severe mucus deficiency syndromes.

Authors:  H Wenkel; V Rummelt; G O Naumann
Journal:  Br J Ophthalmol       Date:  2000-03       Impact factor: 4.638

2.  Amniotic membrane transplantation for severe neurotrophic corneal ulcers.

Authors:  H J Chen; R T Pires; S C Tseng
Journal:  Br J Ophthalmol       Date:  2000-08       Impact factor: 4.638

3.  Amniotic membrane transplantation for partial limbal stem cell deficiency.

Authors:  D F Anderson; P Ellies; R T Pires; S C Tseng
Journal:  Br J Ophthalmol       Date:  2001-05       Impact factor: 4.638

Review 4.  Amniotic membrane transplantation.

Authors:  H S Dua; A Azuara-Blanco
Journal:  Br J Ophthalmol       Date:  1999-06       Impact factor: 4.638

5.  Immunosuppressive properties of human amniotic membrane for mixed lymphocyte reaction.

Authors:  M Ueta; M-N Kweon; Y Sano; C Sotozono; J Yamada; N Koizumi; H Kiyono; S Kinoshita
Journal:  Clin Exp Immunol       Date:  2002-09       Impact factor: 4.330

6.  Transplantation of cultivated autologous oral mucosal epithelial cells in patients with severe ocular surface disorders.

Authors:  T Nakamura; T Inatomi; C Sotozono; T Amemiya; N Kanamura; S Kinoshita
Journal:  Br J Ophthalmol       Date:  2004-10       Impact factor: 4.638

7.  [Corneal wound healing. II. Treatment of disorders of wound healing].

Authors:  P W Rieck; U Pleyer
Journal:  Ophthalmologe       Date:  2003-12       Impact factor: 1.059

8.  ABCG2-dependent dye exclusion activity and clonal potential in epithelial cells continuously growing for 1 month from limbal explants.

Authors:  Ozlëm Barut Selver; Alexander Barash; Mohaned Ahmed; J Mario Wolosin
Journal:  Invest Ophthalmol Vis Sci       Date:  2011-06-17       Impact factor: 4.799

9.  Cultured corneal epithelia for ocular surface disease.

Authors:  I R Schwab
Journal:  Trans Am Ophthalmol Soc       Date:  1999

Review 10.  Autologous serum eye drops for ocular surface disorders.

Authors:  G Geerling; S Maclennan; D Hartwig
Journal:  Br J Ophthalmol       Date:  2004-11       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.